Compare CHR & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | ELTX |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.4M | 141.3M |
| IPO Year | N/A | N/A |
| Metric | CHR | ELTX |
|---|---|---|
| Price | $1.59 | $8.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 387.8K | 89.8K |
| Earning Date | 07-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 96.06 | N/A |
| Revenue | ★ $147,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $4.60 |
| 52 Week High | $141.71 | $12.62 |
| Indicator | CHR | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 79.11 | 47.38 |
| Support Level | $1.30 | $7.77 |
| Resistance Level | $1.65 | $8.64 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 94.08 | 37.89 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerReal, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.